Please login to the form below
biologics
This page shows the latest biologics news and features for those working in and with pharma, biotech and healthcare.
J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial
clutch of new biologic therapies elbowing for market share in the increasingly crowded psoriasis category.
Latest news
-
FDA takes aim at pharma’s biosimilar-delaying tactics
He said there have been cases of biologic drug producers using these systems as an excuse not to supply biosimilar developers with the reference samples needed to carry out the necessary ... even though they are biologics, but that will change in March
-
As France protests, Sanofi takes axe to 670 jobs
The group also said it plans to invest 700m in France to upgrade its production sites, notably in the areas of vaccines manufacturing and other biologic medicines.
-
AZ says target of $45bn sales by 2023 still achievable
patient prescriptions in the US and Germany and topping all biologics for asthma on that measure in Japan.
-
Novartis: pipeline will generate 60 filings in three years
Also in that category and in late-stage clinical development are CRTH2 antagonist QAW039 (fevipiprant) for moderate-to-severe asthma – which it says combines the efficacy of new biologic drugs with
-
Dupixent helps put Sanofi back on growth track
Approval is asthma could help drive sales of the drug above the $7.5bn mark, according to Leerink analysts, as it is the only asthma biologic that patients can self-administer
More from news
Approximately 18 fully matching, plus 499 partially matching documents found.
Latest Intelligence
-
AstraZeneca’s oncology renaissance
Imfinzi, competing in the hypercompetitive world of immuno-oncology, was developed by MedImmune, the company’s US-based biologics research division, while the two small molecule drugs were developed in the ... The third area is immuno-oncology (IO)
-
Deal Watch October 2018
non‐biologic product post‐patent loss, highlighting the benefits of biologics in the long term and the complexities of developing and manufacturing them. ... $307m. Samsung Bioepis/. Merck &Co. Lusduna Nexvue follow‐on biologic. Termination. $155m.
-
Nudge-nudge, think-think
The power of achieving the triad of capability, opportunity and peer endorsement is evidenced by a recent study into how to avoid retrograde outcomes when switching patients from biologics to biosimilars.
-
Making Europe a leader in bioscience: boosting trust and opening minds
New disruptive innovation is changing the way we create value in healthcare: big data, artificial intelligence, the growing role of patients, the discovery of new materials and biologics, gene, cell and
-
AstraZeneca: building a new ‘open innovation’ pharma company
and biologics housed under the same roof. ... Co-locating scientists who work on chemistry and small molecule drug development with scientists who work on biologics, large molecules and protein based therapeutics, in lab-based environments for the first
More from intelligence
Approximately 2 fully matching, plus 71 partially matching documents found.
Latest appointments
-
BMS appoints new commercial leader, Davies joins Eisai and more
Commenting on her appointment, Schuermans said: “Sobi has unique capabilities, a heritage in biologics manufacturing, development and supply, and a very exciting future within the rare disease space.
-
Industry appointments
Most recently, Hassan built the oncology-focused biology, preclinical and biomarker units for Immunocore, overseeing early development and the first-in-human trial of a TCR based biologic targeting a melanoma
-
Nabriva Therapeutics appoints chief medical officer
medical affairs for small molecules and biologics.
-
Ipsen appoints Aidan Murphy as EVP, technical operations
He is promoted from senior VP biologics development and manufacturing. Ipsen has added to its executive leadership team in the form of Aidan Murphy, who becomes the biopharma’s executive vice ... being senior vice president biologics development and
-
Andy Busch joins Shire as its CSO and head of research and development
both biologics and small molecules.”.
More from appointments
Approximately 7 fully matching, plus 45 partially matching documents found.
Latest from PMHub
-
NHS medicines optimisation milestone
Consequently, it is hugely significant to the NHS’s best value biologics agenda. ... A key issue to consider in this regard is how patients receive biologic medications.
-
OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months. The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and
-
It’s all about patient outcomes… right?
a novel biologic agent. ... the roll-out of the novel biologic agent was conducted in a manner that was sensitive to the PCP/specialist interaction observed, ensured smooth communications and optimised patient outcomes.
-
Biotech: it's a people business
Biologic therapies have become a central part of modern day medicine and a key part of biotech and pharma portfolios.
-
How integrated insights supported a biologic launch strategy across multiple indications
Our client is launching a new biologic in dermatology across indications and needed to understand the market, including the patient pool, treatment landscape, potential uptake and pricing opportunity for their new
More from PMHub
Approximately 7 fully matching, plus 34 partially matching documents found.
Featured jobs
- Account Manager- Healthcare Advertising
-
Negotiable
- Principal Health Economist - North-West
-
Negotiable
-
Experienced Medical Writers
-
Competitive Salary and Benefits
-
Account Manager
-
Negotiable
- CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...
-
EXCELLENT DAY RATES AVAILABLE
-
Medical (Scientific) Director
-
£120, 000 benefits
-
Medical Writer
-
Salary TBC
-
Account Manager / Account Director
-
Competative
- Business Development Director – Health Education
-
excellent commission
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Associate Medical Director
-
Excellent PTO, bonus and 401k package
-
Systematic Reviewer - Oxford
-
Negotiable
- Manager - Immunology, Therapeutic Area Communications & Publ...
-
Competitive Salary Offered
-
Business Director
-
Competitive Salary Offered
- Account Executive/ Senior Account Executive
-
competitive Salary Offfered
-
Senior Account Manager
-
Competitive Salary Offered
-
Account Director
-
Competitive Salary Offered
Subscribe to our email news alerts
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....
Latest intelligence
- AstraZeneca’s oncology renaissance
- Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
- Navigating the antibiotic resistance crisis
- Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
- Combined immunotherapies – potential and pitfalls
- ‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Quick links
Infographics
